1.
Comparative study of Cu-based bimetallic oxides for Fenton-like degradation of organic pollutants.
Wang, Q, Ma, Y, Xing, S
Chemosphere. 2018;:450-456
Abstract
In order to provide useful information for the rational design of effective Fenton-like catalyst, a series of Cu-based bimetallic oxides were synthesized and their Fenton-like performances for the degradation of Orange II and ciprofloxacin were compared. The structure, chemical oxidation state, surface charge property and redox ability of the catalysts were also investigated by different characterization techniques. Among them, NiCu exhibited the highest adsorption capacity towards Orange II and the highest activity for the production of OH from H2O2 decomposition, which could be attributed to its high surface area and highly positively charged surface. However, FeCu exhibited the highest activity for the degradation of Orange II. The reason might be that FeCu has more unpaired electrons and higher redox ability, thus promoting the activation of adsorbed Orange II through the electron transfer process. By contrast, NiCu exhibited the highest activity for the removal of ciprofloxacin because ciprofloxacin was mainly degraded by OH. Finally, the main degradation intermediates of Orange II and ciprofloxacin were determined by liquid chromatography-mass spectrometry.
2.
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma, Y, Liu, L, Jin, J, Lou, Y
PloS one. 2016;(7):e0158760
Abstract
BACKGROUND Recently, the all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) protocol has become a promising first-line therapeutic approach in patients with newly diagnosed acute promyelocytic leukemia (APL), but its benefits compared with standard ATRA plus chemotherapy regimen needs to be proven. Herein, we conducted a meta-analysis comparing the efficacy of ATRA plus ATO with ATRA plus chemotherapy for adult patients with newly diagnosed APL. METHODS We systematically searched biomedical electronic databases and conference proceedings through February 2016. Two reviewers independently assessed all studies for relevance and validity. RESULTS Overall, three studies were eligible for inclusion in this meta-analysis, which included a total of 585 patients, with 317 in ATRA plus ATO group and 268 in ATRA plus chemotherapy group. Compared with patients who received ATRA and chemotherapy, patients who received ATRA plus ATO had a significantly better event-free survival (hazard ratio [HR] = 0.38, 95% confidence interval [CI]: 0.22-0.67, p = 0.009), overall survival (HR = 0.44, 95% CI: 0.24-0.82, p = 0.009), complete remission rate (relative risk [RR] = 1.05; 95% CI: 1.01-1.10; p = 0.03). There were no significant differences in early mortality (RR = 0.48; 95% CI: 0.22-1.05; p = 0.07). CONCLUSION Thus, this analysis indicated that ATRA plus ATO protocol may be preferred to standard ATRA plus chemotherapy protocol, particularly in low-to-intermediate risk APL patients. Further larger trials were needed to provide more evidence in high-risk APL patients.